Clardy, Stacey L. http://orcid.org/0000-0001-6600-9428
Pittock, Sean J.
Aktas, Orhan
Nakahara, Jin
Isobe, Noriko
Centonze, Diego
Fam, Sami
Kielhorn, Adrian
Yu, Jeffrey C.
Jansen, Jeroen
Zhang, Ina
Funding for this research was provided by:
Alexion Pharmaceuticals
Article History
Received: 15 December 2023
Accepted: 23 February 2024
First Online: 9 May 2024
Change Date: 14 June 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40120-024-00638-1
Declarations
:
: Stacey L. Clardy is an employee of the University of Utah and the Salt Lake City VA. She and her institution have received research support from NIH/NINDS (U01, The ExTINGUISH Trial), the Western Institute for Veteran Research, the Siegel Rare Neuroimmune Association, the Immune Deficiency Foundation, Viela Bio/Horizon, Alexion/AstraZeneca, the Barbara Gural Steinmetz Foundation, and the Sumaira Foundation for NMO, and consulting/advisory board fees from Alexion, VielaBio/Horizon, and Genentech/Roche. Sean J. Pittock has received personal compensation for serving on scientific advisory boards for F. Hoffmann-La Roche (which manufactures satralizumab, an approved targeted therapy for NMOSD) and his institution has received grants; his institution has received grants, personal fees, nonfinancial support, research support, and compensation for serving as a consultant for Alexion, AstraZeneca Rare Disease (which holds the patent rights to ravulizumab and eculizumab). He holds Patent # 9,891,219B2, Application # 12–573,942, Methods for Treating Neuromyelitis Optica (NMO) by Administration of Eculizumab to an Individual That Is Aquaporin-4 (AQP4)-IgG Autoantibody Positive, which has been issued and for which he has received royalties. He also reports grants, personal fees, nonfinancial support, and other support from Horizon, MedImmune (which produces inebilizumab). Orhan Aktas reports grants from the German Ministry of Education and Research (BMBF) and the German Research Foundation (DFG); grants and personal fees from Biogen, Genzyme, Novartis, and Teva, and personal fees from Alexion, Almirall, Bristol Myers Squibb, Horizon Therapeutics, Merck Serono, and Roche, and is a member of the European Reference Network for Rare Eye Diseases (ERN-EYE), co-funded by the Health Program of the European Union under the Framework Partnership Agreement No 739434 ‘ERN-EYE’. Jin Nakahara reports personal fees from AbbVie, Alexion Pharma GK, Asahi Kasei Medical, Biogen, Bristol Myers Squibb, Chugai, CSL Behring, Daiichi Sankyo, Eisai, Kyorin, Mitsubishi Tanabe Pharma, Novartis, Otsuka, Roche, Takeda, and Teijin Pharma; research scholarships from AbbVie, Boehringer Ingelheim, Chugai, Daiichi Sankyo, EA Pharma, Eisai, JB, Mitsubishi Tanabe Pharma, Otsuka, Shionogi, Sumitomo Pharma, Teijin Pharma, and Tsumura; and grants from the Ministry of Education, Science and Technology of Japan, the MHLW, and Biogen. Noriko Isobe reports speaker honorarium from Alexion Pharma GK, Biogen Japan, Chugai, CSL Behring, Daiichi Sankyo, Eisai, Mitsubishi Tanabe Pharma, Novartis, Takeda Pharma, Teijin Pharma; research grants from Teijin Pharma, Chugai; and collaborative research with Biogen Japan. Diego Centonze is an employee of the University of Rome Tor Vergata. Sami Fam is an employee and stockholder of Alexion Pharmaceuticals. Adrian Kielhorn is an employee and stockholder of Alexion Pharmaceuticals. Jeffrey Yu is an employee and stockholder of Alexion Pharmaceuticals. Jeroen Jansen is an employee of PRECISIONheor, a consultancy firm, which received funding from Alexion Pharmaceuticals to support this work. Ina Zhang is an employee of PRECISIONheor, a consultancy firm, which received funding from Alexion Pharmaceuticals to support this work.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.